LCK and neoplasm: Targeting the inhibition of the LCK-14-3-3ζ-TRPM8 axis to impair oncogene function of both TRPM8 and LCK may enhance tumor sensitivity to therapeutics, allowing for potential pharmacological targeting for anticancer therapy.